All In Biotech

Drug Trial Radar · NCT02184689

Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study

Last checked: Nov 20, 2026Latest source record: Jun 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

May 3, 2014

Primary completion

Dec 14, 2016

Study completion Jun 27, 2017

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the efficacy and safety of an oral regimen of fexinidazole (once daily for 10 days) in the treatment of stage 1 and stage 2 T.b. gambiense sleeping sickness in children at least 6 years old and over 20 kg bodyweight.

Conditions

  • Human African Trypanosomiasis (HAT)

Interventions

  • fexinidazoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Outcome (success or failure) at the test of cure (ToC)Time frame: 12 months after the end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Kinshasa, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.